Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).
JAMM AQUINO / JAQUINO @STARADVERTISER.COM State Epidemiologist Dr. Sarah Kemble said Thursday that the state Department of Health is not yet able to determine whether the specimen collected last week ...
The Food and Drug Administration (FDA) recently announced it is considering banning a common ingredient in popular over-the-counter cold medications. Andrew Wong, MD, ...